首页> 外文期刊>Cardiovascular therapeutics >Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases.
【24h】

Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases.

机译:先天性免疫和通行费样受体拮抗剂:在心血管疾病的治疗中具有潜在作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Toll-like receptors (TLRs) are germline-encoded receptors that recognize various pathogen-associated molecular patterns (PAMPs). They are key components of the innate immunity which are activated in response to pathogens as well as non-pathogenic components of damaged tissues. TLR agonists have been developed to treat allergies, cancers, and chronic infections by upregulating the innate immune system. TLR antagonists may be used to treat a number of inflammatory conditions, such as rheumatoid arthritis and systemic lupus erythematosus. Recent research also has shown that TLRs are involved in the pathogenesis of atherosclerosis, thrombosis, myocardial remodeling, ischemic/reperfusion injury, and valvular disease. This article reviews the current experimental and clinical evidence for the role of TLRs in the cardiovascular system, and examines the mechanisms by which TLR antagonists could potentially be used in targeted therapy.
机译:Toll样受体(TLR)是种系编码的受体,可识别各种病原体相关的分子模式(PAMP)。它们是先天免疫的关键组成部分,可响应病原体以及受损组织的非病原性组件而被激活。已经开发出TLR激动剂,通过上调先天免疫系统来治疗过敏,癌症和慢性感染。 TLR拮抗剂可用于治疗多种炎症,例如类风湿关节炎和系统性红斑狼疮。最近的研究还表明,TLR与动脉粥样硬化,血栓形成,心肌重塑,缺血/再灌注损伤和瓣膜病的发病机制有关。本文回顾了TLR在心血管系统中的作用的当前实验和临床证据,并探讨了TLR拮抗剂可能用于靶向治疗的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号